The Ebola outbreak in the Democratic Republic of Congo has killed at least 2,011 people out of 4,381 confirmed cases across five provinces, Congolese health officials reported on August 11, making it the fastest-growing and now the second-deadliest Ebola epidemic in history. Approximately 1,000 of those deaths occurred in the last three weeks alone, a rate of acceleration that the World Health Organization has described as unprecedented for an Ebola event. The pathogen driving the outbreak is the Bundibugyo ebolavirus, a less-studied species for which no approved vaccine or targeted treatment exists, complicating a response that is already hampered by armed conflict, population displacement, and gaps in surveillance across eastern Congo’s most unstable provinces.
Key Takeaways
- As of August 11, the DRC has recorded 4,381 confirmed Ebola cases and 2,011 deaths, with a case fatality rate of 45.9%; the outbreak has spread across 53 health zones in five provinces.
- During the most recent complete reporting week, 567 new cases and 296 deaths were recorded, the highest weekly figures since the outbreak began.
- The outbreak was officially declared on May 15, 2026, in Ituri Province, but the WHO has said infections likely began in January or February in the town of Mongbwalu.
- The pathogen is the Bundibugyo ebolavirus, not the Zaire ebolavirus used in existing Ebola vaccines; no approved vaccine or specific antiviral treatment exists for Bundibugyo virus disease.
- The outbreak has now surpassed the 2018-2020 DRC Ebola epidemic (3,317 confirmed cases) to become the largest Ebola outbreak ever recorded in the country.
- Two imported cases have been reported outside Africa, both in aid workers evacuated to Germany and France; the WHO’s International Health Regulations Emergency Committee will convene on August 18.
The Numbers Are Moving Faster Than Any Prior Ebola Event
The trajectory of this outbreak has no precedent in the history of Ebola surveillance. The WHO’s most recent Disease Outbreak News, published August 1 with data through July 30, reported 3,605 confirmed cases and 1,587 deaths. Between July 17 and July 30 alone, 1,481 new confirmed cases and 759 deaths were added. While the WHO noted that part of this increase reflects expanded surveillance and laboratory testing, the majority represents genuine expansion of the outbreak into new populations and geographies.
Congolese government data released on August 11 showed the toll had risen further to 4,381 cases and 2,011 deaths. The acceleration has been stark: approximately 1,000 of those deaths occurred in the three weeks preceding August 11. During epidemiological week 30, the most recent complete reporting week in the WHO data, 567 new confirmed cases and 296 deaths were recorded, both all-time highs for any single week in this outbreak.
The numbers place this epidemic firmly in the category of the world’s worst Ebola events. It has already surpassed the 2018-2020 DRC outbreak, which produced 3,317 confirmed cases and 2,287 deaths over two years, in total case count. In death toll, it trails only the 2013-2016 West Africa epidemic, which killed 11,325 people across Guinea, Liberia, and Sierra Leone. Sania Nishtar, CEO of the Gavi global vaccine alliance, said the current outbreak “could well become the largest Ebola outbreak ever.”
Ituri Province Remains the Epicenter
The geographic concentration of the outbreak in Ituri Province, in the country’s northeast, defines both the scale and the complexity of the response. As of July 30, Ituri accounted for 88% of all confirmed cases (3,176 of 3,605) and 82.6% of all deaths (1,311 of 1,587). Within the province, the hardest-hit health zones are Bunia (880 cases), Rwampara (627 cases), Mongbwalu (541 cases), and Nizi (377 cases).
From Ituri, the virus has spread south and east into North Kivu (11 health zones affected), South Kivu (1 health zone), and north into Haut-Uele (5 health zones) and Tshopo (4 health zones). Of the 53 health zones reporting cases, 33 remained active as of the most recent data, meaning they had recorded at least one confirmed case in the prior seven days.
The outbreak is unfolding in one of the most complex humanitarian environments in the world. Eastern DRC has been gripped by armed conflict for decades, with dozens of militia groups operating across Ituri, North Kivu, and South Kivu. Population displacement is constant: hundreds of thousands of internally displaced people live in overcrowded camps where sanitation is limited and disease transmission is accelerated. Armed attacks on health facilities have disrupted response operations, restricted access for medical teams, and increased the risk of undetected transmission chains persisting in areas that response workers cannot reach.
The Bundibugyo Virus Presents a Distinct Challenge
This outbreak is caused by the Bundibugyo ebolavirus, one of six known species in the Orthoebolavirus genus but one that has received far less research attention than the Zaire ebolavirus, which caused the 2013-2016 West Africa epidemic and the 2018-2020 DRC outbreak. The distinction is consequential: the two currently approved Ebola vaccines, Ervebo (manufactured by Merck) and Zabdeno/Mvabea (manufactured by Johnson & Johnson), were developed specifically against the Zaire ebolavirus and are not approved for use against the Bundibugyo strain.
No approved vaccine or specific antiviral treatment exists for Bundibugyo virus disease. The WHO convened the Strategic Advisory Group of Experts on Immunization (SAGE) on May 28 to assess candidate vaccines and therapeutics, but none have completed clinical trials for this pathogen. Response teams are relying on the traditional pillars of Ebola control: rapid case identification, isolation and supportive care, contact tracing, safe and dignified burials, and community engagement to reduce transmission.
The Bundibugyo virus has caused only two prior documented outbreaks: one in Uganda in 2007 (with a 30% case fatality rate) and one in DRC in 2012 (with a 50% CFR). The current outbreak’s 45.9% CFR falls between those two benchmarks. The virus is transmitted through direct contact with bodily fluids of infected individuals and is not airborne. The incubation period ranges from 2 to 21 days, and infected individuals are not contagious until they develop symptoms.
Health Worker Infections Highlight Systemic Vulnerabilities
The outbreak has infected 151 health workers, killing 44 of them for a 29% case fatality rate. Another 68 health workers have recovered. These infections reflect what the WHO described as “ongoing occupational exposure risks, persistent challenges in implementing infection prevention and control in healthcare facilities, and continued exposure risk in the community.”
Health worker infections are both a humanitarian crisis and a functional one. Every infected nurse, doctor, or community health volunteer removed from the response reduces the capacity of a system already operating below what is needed. The WHO’s August 1 assessment stated explicitly that “a substantial scaling up of response activities is needed to get ahead of the outbreak,” a rare acknowledgment from the organization that current efforts are not keeping pace with transmission.
Contact tracing, a cornerstone of Ebola control, illustrates the gap. As of July 30, 17,863 contacts had been identified across the four active provinces. Of those, 13,455 were under active follow-up, representing follow-up rates that ranged from 66.2% in Tshopo to 80.6% in Haut-Uele. In an Ebola response, every contact who is not traced and monitored represents a potential undetected transmission chain.
International Spread Has Been Limited but Not Zero
The outbreak has produced confirmed cases outside Africa, though secondary transmission from those cases has not occurred. Uganda reported 20 confirmed cases and 2 deaths before declaring the end of its outbreak on July 28, following 42 days without a new locally transmitted case. The WHO noted that Uganda remains at risk of reimportation given the ongoing transmission in neighboring DRC and the volume of cross-border movement along the eastern DRC-western Uganda corridor.
A French aid worker deployed to support the DRC response tested positive on June 24 after returning to France. The patient recovered and was discharged on July 4 after two consecutive negative PCR results. All identified contacts completed their 21-day follow-up without developing symptoms. On July 10, the U.S. Centers for Disease Control and Prevention reported that an American citizen working for a humanitarian organization in DRC had tested positive for the Bundibugyo virus. The patient was medically evacuated to Germany on July 13. A second aid worker had previously been evacuated to Germany for treatment earlier in the outbreak. Both recovered.
The European Centre for Disease Prevention and Control assessed the likelihood of infection for people in the EU/EEA as “very low” but noted significant surveillance gaps in the DRC. The WHO’s global risk assessment also remains at “low” outside Africa, though the organization has scheduled an IHR Emergency Committee meeting for August 18 to reassess the situation and potentially update its temporary recommendations.
The Response Is Outpaced by Transmission
Congolese health authorities, the WHO, and international partners are implementing a continental preparedness and response plan, a six-month framework covering emergency coordination, surveillance, laboratory testing, infection prevention, clinical care, community engagement, and logistics. The plan was developed jointly by the WHO and the Africa CDC and launched on June 5.
However, the operational reality on the ground is shaped by constraints that no plan can fully address. Armed groups have attacked health facilities in affected provinces. Insecurity restricts access to some of the hardest-hit health zones. Population mobility, driven by displacement, cross-border trade, and mining activities, creates pathways for the virus to reach new communities before response teams can establish containment measures. The WHO’s risk assessment for the DRC remains at “very high,” and the assessment for countries sharing land borders with the DRC remains at “high.”
The funding environment adds another layer of difficulty. Médecins Sans Frontières described the epidemic in July as “the third largest, and fastest growing, Ebola disease outbreak on record,” adding that communities outside of major urban areas “remain without adequate support.” The Norwegian Refugee Council, responding to the Colombia earthquake, noted that the DRC outbreak “compounds an already severe humanitarian situation” in a region where poverty, displacement, and conflict have persisted for decades.
What Comes Next
The IHR Emergency Committee meeting on August 18 will be the next formal international checkpoint for the outbreak. The committee will assess whether the current temporary recommendations, issued on May 22, need to be updated in light of the accelerating case count, the geographic expansion, and the continued absence of an approved vaccine for the Bundibugyo strain.
The trajectory of the next four to six weeks will likely determine whether this outbreak remains a regional crisis or becomes a global one. If transmission continues at its current pace, the cumulative case count will surpass the 2018-2020 DRC outbreak’s death toll within days, and the total case count could approach the 2013-2016 West Africa epidemic’s scale by late 2026. The WHO has not recommended travel or trade restrictions with affected countries, a position that will face increasing scrutiny if imported cases continue to appear in Europe and the response continues to lag behind transmission.
Disclaimer: This article is provided for informational and educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Information about Ebola virus disease, including symptoms, transmission, vaccines, treatments, case numbers, and public-health risks, can change as health authorities receive new data. The article discusses the Bundibugyo ebolavirus outbreak and should not be used as a substitute for guidance from qualified healthcare professionals or official public-health authorities. Anyone who believes they may have been exposed to Ebola or is experiencing symptoms consistent with Ebola virus disease should seek immediate medical attention and follow instructions from local health authorities. Do not attempt to diagnose or treat Ebola based solely on information presented in this article. For current outbreak information, readers should consult authoritative sources such as the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention (CDC), and relevant national or local health authorities.
FAQs
How many people have died in the DRC Ebola outbreak?
As of August 11, 2026, at least 2,011 people have died out of 4,381 confirmed cases across five provinces in the Democratic Republic of Congo. The case fatality rate stands at 45.9%. Approximately 1,000 of those deaths occurred in the three weeks preceding the August 11 data update.
What type of Ebola virus is causing this outbreak?
The outbreak is caused by the Bundibugyo ebolavirus, a less-studied species in the Orthoebolavirus genus. It is distinct from the Zaire ebolavirus, which caused the 2013-2016 West Africa epidemic and for which two vaccines (Ervebo and Zabdeno/Mvabea) are approved. No approved vaccine or specific treatment exists for Bundibugyo virus disease.
Has the virus spread outside of Africa?
Two imported cases have been reported outside Africa, both in aid workers. A French aid worker tested positive in France on June 24 and recovered by July 4. An American humanitarian worker tested positive in DRC on July 10 and was evacuated to Germany for treatment. No secondary transmission has occurred from either case. Uganda reported 20 confirmed cases and 2 deaths before declaring its outbreak over on July 28.
When did the outbreak start?
The outbreak was officially declared on May 15, 2026, in Ituri Province. However, the WHO has said infections likely began in January or February 2026 in the town of Mongbwalu. The delay in detection was partly because initial diagnostic tests screened only for the Zaire ebolavirus and returned negative results before Bundibugyo-specific testing was deployed.
